NTLA FY 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+16.9% YoY

Gross Profit

$52M76.5% margin

Operating Income

-$441M-651.7% margin

Net Income

-$413M-609.9% margin

EPS (Diluted)

$-3.81

Cash Flow

Operating Cash Flow

-$349M

Free Cash Flow

-$355M

Stock-Based Comp.

$154M

Balance Sheet

Total Assets

$842M

Total Liabilities

$171M

Stockholders' Equity

$671M

Cash & Equivalents

$155M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$58M	+16.9%
Gross Profit	$52M	$48M	+8.7%
Operating Income	-$441M	-$534M	+17.5%
Net Income	-$413M	-$519M	+20.5%